Abstract: |
In spite of large number of clinical trial addressing the role of adjuvant chemotherapy and radiation therapy in the treatment of oesophageal and gastric cancer, a survival benefit has yet to be demonstrated, and surgery alone remains the standard of care. With regard to cancers of the colon and rectum, the situation is considerably different. For patients with Dukes C colon cancer, postoperative adjuvant chemotherapy with a combination of 5-fluorouracil and levamisole has now been demonstrated to result in a statically significant benefit on both progression-free and overall survival, and is now recommended as standard therapy. For patients with Dukes B2 and C rectal cancer, standard therapy is postoperative treatment with 5- fluorouracil-based chemotherapy and concurrent pelvic radiotherapy. Clinical trials addressing the issue of postoperative adjuvant therapy in gastrointestinal cancers are ongoing. These trials are currently addressing issues such as timing of therapy and route of delivery of therapy as well continued evaluation of new chemotherapeutic agents, and optimal regimens. |